334 related articles for article (PubMed ID: 27190342)
41. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
42. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
43. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
Brooks JM; Chapman CG; Suneja M; Schroeder MC; Fravel MA; Schneider KM; Wilwert J; Li YJ; Chrischilles EA; Brenton DW; Brenton M; Robinson J
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29848495
[TBL] [Abstract][Full Text] [Related]
44. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.
Chien SC; Ou SM; Shih CJ; Chao PW; Li SY; Lee YJ; Kuo SC; Wang SJ; Chen TJ; Tarng DC; Chu H; Chen YT
Medicine (Baltimore); 2015 Oct; 94(43):e1751. PubMed ID: 26512568
[TBL] [Abstract][Full Text] [Related]
45. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
46. Effects of ACEIs and ARBs on the Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials.
Ding L; Yang J; Li L; Yang Y
Biomed Res Int; 2020; 2020():6762029. PubMed ID: 33029520
[TBL] [Abstract][Full Text] [Related]
47. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
48. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
50. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
[TBL] [Abstract][Full Text] [Related]
51. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
52. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
53. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
54. Primary prevention of cardiovascular disease events with renin-angiotensin system blockade in autosomal dominant polycystic kidney disease dialysis patients: A nationwide cohort study.
Lu CL; Lin CY; Lin LY; Chen PC; Zheng CM; Lu KC; Yeih DF
Medicine (Baltimore); 2021 Jul; 100(26):e26559. PubMed ID: 34190195
[TBL] [Abstract][Full Text] [Related]
55. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
[TBL] [Abstract][Full Text] [Related]
56. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure.
Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP
Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454
[TBL] [Abstract][Full Text] [Related]
57. Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Hsu FY; Lin FJ; Ou HT; Huang SH; Wang CC
Kidney Blood Press Res; 2017; 42(2):358-368. PubMed ID: 28618426
[TBL] [Abstract][Full Text] [Related]
58. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
[TBL] [Abstract][Full Text] [Related]
59. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with diabetes mellitus and non-ST-segment elevation myocardial infarction who underwent successful percutaneous coronary intervention.
Byun JK; Choi BG; Rha SW; Choi SY; Jeong MH;
Atherosclerosis; 2018 Oct; 277():130-135. PubMed ID: 30212681
[TBL] [Abstract][Full Text] [Related]
60. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]